top of page
Browse by category
Search
Where people shop for their food and the risk of obesity-related cancers
A team of researchers at the University of Connecticut have developed a novel tool to help understand consumer behaviour at the county...
Antag begins trial of AT-7687, a GIPR antagonist designed to address key gaps in obesity treatment
Antag Therapeutics has initiated its first-in-human Phase 1 clinical trial evaluating AT-7687, a first-in-class Glucose-Dependent...
BariPredict: Class II obesity, younger age and concurrent depression are risk factors for eating disorders in potential bariatric patients
Outcomes from the BariPredict cohort have found that 65.8% prevalence of persons at risk of an eating disorder (ED) - opting for, but not...
MC4R Agonist bremelanotide co-administered with tirzepatide meets primary endpoint
Palatin Technologies’ BMT-801 Phase 2 obesity co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like...
Magnetic bipartition feasible, safe and effective in achieving incisionless, suture/staple-free duodeno-ileostomy
An innovative technique using a biofragmentable magnetic anastomosis system (BMAS) to effect magnetic duodeno-ileostomy (MagDI)...
WL Gore launches Gore SYNECOR preperitoneal biomaterial in Europe, the Middle East and South Africa
WL Gore & Associates (Gore) has announced that GORE SYNECOR Preperitoneal Biomaterial is now available in Europe, Middle East and South...
Browse by tag
bottom of page